Miguel
Alcoceba Sánchez
Investigador desde 2011
Complejo Asistencial de Segovia
Segovia, EspañaPublicaciones en colaboración con investigadores/as de Complejo Asistencial de Segovia (10)
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
2020
-
Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients
British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730
2018
-
Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study
Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484
2014
-
Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia
BioMed Research International, Vol. 2014
2013
-
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia
Leukemia, Vol. 27, Núm. 8, pp. 1722-1728
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Blood, Vol. 114, Núm. 1, pp. 148-152
2008
-
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Haematologica, Vol. 93, Núm. 12, pp. 1797-1805